These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19645482)

  • 21. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.
    Imig JD
    Cardiovasc Drug Rev; 2006; 24(2):169-88. PubMed ID: 16961727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
    Kim IH; Tsai HJ; Nishi K; Kasagami T; Morisseau C; Hammock BD
    J Med Chem; 2007 Oct; 50(21):5217-26. PubMed ID: 17894481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.
    Takai K; Nakajima T; Takanashi Y; Sone T; Nariai T; Chiyo N; Nakatani S; Ishikawa C; Yamaguchi N; Fujita K; Yamada K
    Bioorg Med Chem; 2014 Mar; 22(5):1548-57. PubMed ID: 24530032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
    Taylor SJ; Soleymanzadeh F; Eldrup AB; Farrow NA; Muegge I; Kukulka A; Kabcenell AK; De Lombaert S
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5864-8. PubMed ID: 19758802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition.
    Davis BB; Morisseau C; Newman JW; Pedersen TL; Hammock BD; Weiss RH
    J Pharmacol Exp Ther; 2006 Feb; 316(2):815-21. PubMed ID: 16221742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
    J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.
    Ulu A; Appt S; Morisseau C; Hwang SH; Jones PD; Rose TE; Dong H; Lango J; Yang J; Tsai HJ; Miyabe C; Fortenbach C; Adams MR; Hammock BD
    Br J Pharmacol; 2012 Mar; 165(5):1401-12. PubMed ID: 21880036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent urea and carbamate inhibitors of soluble epoxide hydrolases.
    Morisseau C; Goodrow MH; Dowdy D; Zheng J; Greene JF; Sanborn JR; Hammock BD
    Proc Natl Acad Sci U S A; 1999 Aug; 96(16):8849-54. PubMed ID: 10430859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of potent inhibitors of soluble epoxide hydrolase by combinatorial library design and structure-based virtual screening.
    Xing L; McDonald JJ; Kolodziej SA; Kurumbail RG; Williams JM; Warren CJ; O'Neal JM; Skepner JE; Roberds SL
    J Med Chem; 2011 Mar; 54(5):1211-22. PubMed ID: 21302953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors.
    Pecic S; Pakhomova S; Newcomer ME; Morisseau C; Hammock BD; Zhu Z; Rinderspacher A; Deng SX
    Bioorg Med Chem Lett; 2013 Jan; 23(2):417-21. PubMed ID: 23237835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of structure-derived pharmacophore of soluble epoxide hydrolase inhibitors by virtual screening.
    Moser D; Achenbach J; Klingler FM; Estel la B; Hahn S; Proschak E
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6762-5. PubMed ID: 23017883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome P450-dependent eicosanoid production and crosstalk.
    Fleming I
    Curr Opin Lipidol; 2011 Oct; 22(5):403-9. PubMed ID: 21825980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.
    Ghosh S; Chiang PC; Wahlstrom JL; Fujiwara H; Selbo JG; Roberds SL
    Basic Clin Pharmacol Toxicol; 2008 May; 102(5):453-8. PubMed ID: 18312493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists.
    Guo L; Ye Z; Liu J; He S; Bakshi RK; Sebhat IK; Dobbelaar PH; Hong Q; Jian T; Dellureficio JP; Tsou NN; Ball RG; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Chen HY; Chen AS; Martin WJ; MacIntyre DE; Strack AM; Fong TM; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4895-900. PubMed ID: 20621473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.
    Burmistrov V; Morisseau C; Danilov D; Harris TR; Dalinger I; Vatsadze I; Shkineva T; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5514-9. PubMed ID: 26520661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
    Yang ZQ; Barrow JC; Shipe WD; Schlegel KA; Shu Y; Yang FV; Lindsley CW; Rittle KE; Bock MG; Hartman GD; Uebele VN; Nuss CE; Fox SV; Kraus RL; Doran SM; Connolly TM; Tang C; Ballard JE; Kuo Y; Adarayan ED; Prueksaritanont T; Zrada MM; Marino MJ; Graufelds VK; DiLella AG; Reynolds IJ; Vargas HM; Bunting PB; Woltmann RF; Magee MM; Koblan KS; Renger JJ
    J Med Chem; 2008 Oct; 51(20):6471-7. PubMed ID: 18817368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.
    Thalji RK; McAtee JJ; Belyanskaya S; Brandt M; Brown GD; Costell MH; Ding Y; Dodson JW; Eisennagel SH; Fries RE; Gross JW; Harpel MR; Holt DA; Israel DI; Jolivette LJ; Krosky D; Li H; Lu Q; Mandichak T; Roethke T; Schnackenberg CG; Schwartz B; Shewchuk LM; Xie W; Behm DJ; Douglas SA; Shaw AL; Marino JP
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3584-8. PubMed ID: 23664879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
    Eldrup AB; Soleymanzadeh F; Taylor SJ; Muegge I; Farrow NA; Joseph D; McKellop K; Man CC; Kukulka A; De Lombaert S
    J Med Chem; 2009 Oct; 52(19):5880-95. PubMed ID: 19746975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern.
    Ostermann AI; Herbers J; Willenberg I; Chen R; Hwang SH; Greite R; Morisseau C; Gueler F; Hammock BD; Schebb NH
    Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):131-7. PubMed ID: 26117215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytochrome P450 metabolites of arachidonic acid may be important mediators in angiotensin II-induced vasoconstriction in the rat mesentery in vivo.
    Chu ZM; Croft KD; Kingsbury DA; Falck JR; Reddy KM; Beilin LJ
    Clin Sci (Lond); 2000 Mar; 98(3):277-82. PubMed ID: 10677385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.